Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021)

Century Therapeutics' (IPSC) quarterly Preferred Stock Liabilities came in at $159.6 million in Q1 2021, up 357.1% on a QoQ basis from $34.9 million in Q4 2020.

Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Century Therapeutics (IPSC) has 2 years of Preferred Stock Liabilities data on file, last reported at $159.6 million in Q1 2021.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $159.6 million in Q1 2021; TTM through Mar 2021 was $159.6 million, a N/A change from a year earlier, with the FY2020 full-year figure at $34.9 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q1 2021 stood at $159.6 million, up from $34.9 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for IPSC reached as high as $159.6 million in Q1 2021 and fell as low as $34.9 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Century Therapeutics 419.84 Mn 285.04 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 159.63 Mn
Dec 31, 2020 34.92 Mn
Sep 30, 2020 34.99 Mn
Jun 30, 2020 34.99 Mn